Clinical health research provider Doctor Evidence has announced a content partnership with IBM Watson Health to supply clinical cancer research data to Watson’s oncology solutions & developer ecosystem. As part of its new Watson Health unit, the solution has already ingested nearly 15 pages of medical content, including over 200 medical textbooks and 300 medical journals.
Content Partnership Details
Doctor Evidence will contribute 2 million additional data points from highly structured, peer-reviewed content, including thousands of clinical papers, conference proceedings, abstracts on remissions, patient survival cases, epidemiology, and drug label data from the U.S. and Europe. This medical information will be added to Watson’s existing corpus of health data that includes content from partners such as the American Society of Clinical Oncology, Cancer.gov, and the Centers for Disease Control and Prevention, among others.
Data provided by Doctor Evidence will also enhance Watson ecosystem partners’ ability to build oncology related apps. Members of the Watson Ecosystem are bringing a variety of apps to market designed to address issues across the healthcare spectrum, from personal health management, to genomic-based health advice, to dermatology and multiple sclerosis. Developers and entrepreneurs building Watson apps have the option of leveraging their own curated data as a corpus of knowledge for Watson, or drawing from corpuses of data in the IBM Watson Content Marketplace.
“Our oncology data contains valuable information that could truly help doctors provide personalized treatment options to their patients,” said Robert Battista, CEO and co-Founder of Doctor Evidence. “By integrating our data with the Watson Ecosystem and Oncology Solutions, we hope to make that information more actionable for clinicians, and we look forward to seeing how app developers will leverage the high-quality clinical evidence we supply.”
The partnership is part of IBM’s recent efforts to help the medical community advance patient-centered care through its new Watson Health unit. Last month, fourteen US and Canadian cancer centers announced it will used IBM Watson to compare a patient’s tumor genetic fingerprints to databases of cancer genes and findings of scientific papers and clinical trials on cancer in a matter of minutes.
